Nuvation Bio Inc (NUVB) Q3 2026 Earnings Call Highlights: IBTROZI Revenue Climbs 18% as ...
Nuvation Bio Inc (NUVB) posted $45 million in Q3 2026 revenue on strong IBTROZI demand and a $663.4 million cash runway, even as a 15% decline in ROS1 new patient starts clouds near-term growth. Related Stocks: NUVB ,